InterAx Biotech

The company, a spin-out of ETH Zurich and the Paul Scherrer Institute, Switzerland, uses high throughput biochemical screening of compounds integrated into an artificial intelligence and cell pathways mathematical modeling process. This platform unlocks previously intractable targets, shortens timelines for drug discovery from years to months and reduces risks. The company focuses on the generation and optimization of drugs which trigger a specific and well characterized effect on signaling pathways, thus leading to higher therapeutic efficacy and reduced risk of toxicity. The company is specialized in GPCR drug discovery and covers hit-generation, hit- to-lead and lead optimization for all targets...

Gpcr,pharmacology,drug discovery,systems biology,machine learning,and ai

Interax biotech operates in the Biotechnology research industry.

Interax biotech's revenue is 11m - 100m

Interax biotech has 11 - 50 employees.